|
|
|
 |
Search published articles |
 |
|
Showing 3 results for Mouth
Omid Ghane Azabadi, Farshideh Didgar, Nader Zarinfar, Fatemeh Rafiei, Zahra Eslamirad,
Volume 19, Issue 4 (1-2019)
Abstract
Background & objectives: Impaired immune system provides favorable conditions for colonization by Acanthamoeba in the human body. In this case control study, we compared the molecular and culture methods in identifying Acanthamoeba in the nasal and oral secretions of HIV+/HIV human.
Methods: In a current case control study, nasal and oral discharge of 53, HIV+ patients and 53, HIV people were evaluated. The nasal and oral secretions of each patient were prepared by sterile swabs and transferred to the laboratory. All samples were cultured but only the positive samples used for molecular analysis.
Results: By cultivation method, of the 53, HIV+ patients, a total of 11 samples, including 5 nasal and 6 oral samples, were contaminated with Acanthamoeba. Of the 53, HIV people, 3 samples of nasal discharge were contaminated with this parasite. The molecular method approved the contamination of 10 samples, including 5 oral and 5 nasal samples from HIV+ patients with this parasite. Statistical analysis showed the rate of infection in HIV+ patients was significantly different compared to HIV people
Conclusion: The results of the current study showed that the rate of Acanthamoeba infection in HIV+ patients was higher than that of HIV- individuals. Also, considering that in the control group (HIV- individuals) only the nasal discharge were infected with the parasite, it seems that in the case group (HIV + patients) the infection of the oral discharge with the parasites is due to the entry of its cysts into the nose and transmission to the mouth
Sadaf Khaki, Nastaran Hadizadeh, Leila Rezaie Shirmard ,
Volume 22, Issue 4 (1-2023)
Abstract
Background & objectives: Due to the existence of various issues and limitations associated with traditional buccal drug delivery systems such as the disability to consume food whilst using topical drugs in the mouth cavity, unpredictable drug release profile, undesirable taste, low patient adherence to therapy, and accelerated drug removal with saliva, these conventional methods are now rapidly becoming replaced with oral thin films as more precise and novel oral drug delivery platforms. The current study aims to discuss the design and characterization of betamethasone-loaded oral thin films with the aim of improved drug delivery in mouth cavity diseases.
Methods: In this study, oral thin films with and without betamethasone were fabricated through the solvent casting method as a common, fast, and affordable technique prior to being evaluated for different physiochemical characteristics including weight, width, surface pH, disintegration period in vitro conditions, and swelling rates as well as drug release profiles at different intervals.
Results: Obtained oral films were demonstrated to possess adequate homogeneity, flexibility, and mechanical resistance. Accordingly, the average surface pH for films without and with betamethasone was equal to 6.75 and 6.66, respectively, which are in notable compatibility with the neutral pH of the oral cavity. Betamethasone-loaded films’ disintegration duration appeared to be superior to that of films without betamethasone and was in close correlation with their higher swelling rates. Further experiments revealed 25-30% drug release in the initial 20 minutes, followed by more than 90% betamethasone release in 360 minutes in a sustained manner.
Conclusion: These results are indicative of betamethasone oral films’ satisfactory physiochemical properties and potential applicability as a sufficient oral drug delivery platform in mouth cavity diseases such as oral lichen planus or recurrent mouth sores. By sticking to the mouth mucosa, these films can significantly reduce drug removal with saliva and thus ameliorate sufficient delivery of therapeutic agents to specific mouth lesions. Moreover, they can alleviate some of the issues and limitations of traditional topical oral drug delivery and improve treatment or control of disease symptoms.
Taher Sadeghian, Saeideh Allahyari,
Volume 24, Issue 1 (4-2024)
Abstract
Background: Oral mucositis as a complication of chemotherapy has posed significant challenges to the quality of life in cancer patients. Tricyclic antidepressants, including nortriptyline can control the pain caused by mucositis by inhibiting sodium channels. Since patient compliance and rapid drug effect are the goals of the proposed formulation, it was decided to prepare and evaluate a nortriptyline mouthwash according to the United States Pharmacopeia.
Methods: Based on the pharmacopeia, the necessary excipients in the nortriptyline mouthwash were determined, and the amount of each was specified. After validating the UV spectrophotometric technique, drug interaction with the mouthwash container was investigated. In addition to measuring the aqueous activity, necessary microbiological tests were also performed.
Results: The UV spectroscopy method validation for nortriptyline was performed at the obtained maximum absorption wavelength (238.5 nm). The findings of the investigation of the interaction of polyethylene terephthalate container with nortriptyline indicate almost no drug adsorption into the internal part of the mouthwash container over 28 days. The results of antibacterial and antifungal/antimycotic tests were within the standard range of the United States Pharmacopeia. The mouthwash's aqueous activity was also found to be 0.81, indicating an unfavorable environment for microbial growth.
Conclusion: This study has shown that the prepared nortriptyline mouthwash meets microbiological resistance standards and there is no interaction between the active drug ingredient and the proposed container. Therefore, this formulation can be suggested as a promising candidate for clinical exploration.
|
|
.png)
.png)
